Literature DB >> 16038034

Expression of CD86 and increased infiltration of NK cells are associated with Helicobacter pylori-dependent state of early stage high-grade gastric MALT lymphoma.

Sung-Hsin Kuo1, Li-Tzong Chen, Chi-Long Chen, Shin-Lian Doong, Kun-Huei Yeh, Ming-Shiang Wu, Tsui-Lien Mao, Hui-Chen Hsu, Hsiu-Po Wang, Jaw-Town Lin, Ann-Lii Cheng.   

Abstract

AIM: A high percentage of early-stage high-grade gastric mucosa-associated lymphoid tissue (MALT) lymphomas remain Helicobacter pylori (H pylori)-dependent. However, unlike their low-grade counterparts, high-grade gastric MALT lymphomas may progress rapidly if unresponsive to H pylori eradication. It is mandatory to identify markers that may predict the H pylori-dependent status of these tumors. Proliferation of MALT lymphoma cells depends on cognate help and cell-to-cell contact of H pylori-specific intratumoral T-cells. To examine whether the expression of co-stimulatory marker CD86 (B7.2) and the infiltration of CD56 (+) natural killer (NK) cells can be useful markers to predict H pylori-dependent status of high-grade gastric MALT lymphoma.
METHODS: Lymphoma biopsies from 26 patients who had participated in a prospective study of H pylori-eradication for stage I(E) high-grade gastric MALT lymphomas were evaluated. Tumors that resolved to Wotherspoon grade II or less after H pylori eradication were classified as H pylori-dependent; others were classified as H pylori-independent. The infiltration of NK cells and the expression of CD86 in pre-treatment paraffin-embedded lymphoma tissues were determined by immunohistochemistry.
RESULTS: There were 16 H pylori-dependent and 10 H pylori-independent cases. CD86 expression was detected in 11 (68.8%) of 16 H pylori-dependent cases but in none of 10 H pylori-independent cases (P = 0.001). H pylori-dependent high-grade gastric MALT lymphomas contained significantly higher numbers of CD56 (+) NK cells than H pylori-independent cases (2.8+/-1.4% vs 1.1+/-0.8%; P = 0.003). CD86 positive MALT lymphomas also showed significantly increased infiltration of CD56 (+) NK cells compared to CD86-negative cases (2.9+/-1.1% vs 1.4+/-1.3%; P = 0.005).
CONCLUSION: These results suggest that the expression of co-stimulatory marker CD86 and the increased infiltration of NK cells are associated with H pylori-dependent state of early-stage high-grade gastric MALT lymphomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16038034      PMCID: PMC4434662          DOI: 10.3748/wjg.v11.i28.4357

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  Histological grading in gastric lymphoma: pretreatment criteria and clinical relevance.

Authors:  D de Jong; H Boot; P van Heerde; G A Hart; B G Taal
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

Review 2.  Gastric lymphoma: the revolution of the past decade.

Authors:  H Boot; D de Jong
Journal:  Scand J Gastroenterol Suppl       Date:  2002

Review 3.  Role of activated host T cells in the promotion of MALT lymphoma growth.

Authors:  M Guindi
Journal:  Semin Cancer Biol       Date:  2000-10       Impact factor: 15.707

4.  Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma.

Authors:  Susmit Suvas; Vinod Singh; Sudhir Sahdev; Harpreet Vohra; Javed N Agrewala
Journal:  J Biol Chem       Date:  2001-11-28       Impact factor: 5.157

5.  [Clinical staging classification of non-Hodgkin's lymphomas (author's transl)].

Authors:  K Musshoff
Journal:  Strahlentherapie       Date:  1977-04

6.  Structure and dimerization of a soluble form of B7-1.

Authors:  S Ikemizu; R J Gilbert; J A Fennelly; A V Collins; K Harlos; E Y Jones; D I Stuart; S J Davis
Journal:  Immunity       Date:  2000-01       Impact factor: 31.745

7.  Activation of infiltrating cytotoxic T lymphocytes and lymphoma cell apoptotic rates in gastric MALT lymphomas. Differences between high-grade and low-grade cases.

Authors:  M Guidoboni; C Doglioni; L Laurino; M Boiocchi; R Dolcetti
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

8.  Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma.

Authors:  F A Vyth-Dreese; H Boot; T A Dellemijn; D M Majoor; L C Oomen; J D Laman; M Van Meurs; R A De Weger; D De Jong
Journal:  Immunology       Date:  1998-08       Impact factor: 7.397

Review 9.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

10.  Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group.

Authors:  E Bayerdörffer; A Neubauer; B Rudolph; C Thiede; N Lehn; S Eidt; M Stolte
Journal:  Lancet       Date:  1995-06-24       Impact factor: 79.321

View more
  4 in total

Review 1.  Helicobacter pylori eradication in gastric diffuse large B cell lymphoma.

Authors:  Semra Paydas
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

Review 2.  Natural killer (NK) cells in antibacterial innate immunity: angels or devils?

Authors:  Fernando Souza-Fonseca-Guimaraes; Minou Adib-Conquy; Jean-Marc Cavaillon
Journal:  Mol Med       Date:  2012-03-30       Impact factor: 6.354

3.  Detection of the Helicobacter pylori CagA protein in gastric mucosa-associated lymphoid tissue lymphoma cells: clinical and biological significance.

Authors:  S-H Kuo; L-T Chen; C-W Lin; M-S Wu; P-N Hsu; H-J Tsai; C-Y Chu; Y-S Tzeng; H-P Wang; K-H Yeh; A-L Cheng
Journal:  Blood Cancer J       Date:  2013-07-12       Impact factor: 11.037

Review 4.  Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma.

Authors:  Sung-Hsin Kuo; Kun-Huei Yeh; Chung-Wu Lin; Jyh-Ming Liou; Ming-Shiang Wu; Li-Tzong Chen; Ann-Lii Cheng
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.